Creative Planning’s PDL BioPharma, Inc. PDLI Stock Holding History

Creative Planning’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,800	Closed	-$35K	–	2184
2019 Q4	$35K	Sell	10,800 -10,000	-48%	-$29K	﹤0.01%	1847
2019 Q3	$45K	Sell	20,800 -5,000	-19%	-$13.4K	﹤0.01%	1804
2019 Q2	$81K	Sell	25,800 -1,100	-4%	-$3.57K	﹤0.01%	1767
2019 Q1	$100K	Buy	26,900 +1,781	+7%	+$6.01K	﹤0.01%	1710
2018 Q4	$73K	Hold	25,119	–	–	﹤0.01%	1671
2018 Q3	$66K	Buy	25,119 +1,119	+5%	+$2.75K	﹤0.01%	1843
2018 Q2	$56K	Hold	24,000	–	–	﹤0.01%	1840
2018 Q1	$71K	Sell	24,000 -10,000	-29%	-$27.3K	﹤0.01%	1790
2017 Q4	$93K	Sell	34,000 -4,670	-12%	-$14.3K	﹤0.01%	1737
2017 Q3	$131K	Buy	38,670 +2,670	+7%	+$7.42K	﹤0.01%	1683
2017 Q2	$89K	Sell	36,000 -13,350	-27%	-$30.7K	﹤0.01%	2071
2017 Q1	$112K	Sell	49,350 -12,410	-20%	-$27.5K	﹤0.01%	1880
2016 Q4	$131K	Sell	61,760 -4,500	-7%	-$12.6K	﹤0.01%	1687
2016 Q3	$222K	Buy	66,260 +23,410	+55%	+$74.3K	﹤0.01%	1347
2016 Q2	$135K	Buy	42,850 +6,750	+19%	+$22.5K	﹤0.01%	1481
2016 Q1	$120K	Sell	36,100 -14,597	-29%	-$45.5K	﹤0.01%	1521
2015 Q4	$179K	Buy	50,697 +29,314	+137%	+$123K	﹤0.01%	1269
2015 Q3	$108K	Buy	21,383 +7,083	+50%	+$40.6K	﹤0.01%	1555
2015 Q2	$92K	Hold	14,300	–	–	﹤0.01%	985
2015 Q1	$101K	Sell	14,300 -1,157	-7%	-$8.38K	﹤0.01%	1569
2014 Q4	$119K	Sell	15,457 -338	-2%	-$2.67K	﹤0.01%	1456
2014 Q3	$118K	Buy	15,795 +134	+0.9%	+$1.24K	﹤0.01%	1365
2014 Q2	$152K	Sell	15,661 -935	-6%	-$8.33K	﹤0.01%	1190
2014 Q1	$138K	Buy	16,596 +7,120	+75%	+$61K	﹤0.01%	1198
2013 Q4	$80K	Buy	9,476 +2,798	+42%	+$23.6K	﹤0.01%	1329
2013 Q3	$53K	Buy	6,678 +2,788	+72%	+$22.4K	﹤0.01%	1475
2013 Q2	$30K	Buy	+3,890	New	+$30.3K	﹤0.01%	1690

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Creative Planning's PDLI Position: Q1 2020 in Review

Creative Planning sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 10,800 shares — an estimated $35K sold.

Creative Planning first reported a position in PDLI in Q2 2013 and held it in 27 quarters. The position peaked at $222K in Q3 2016. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Creative Planning reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
Creative Planning sold 10,800 PDL BioPharma, Inc. shares in Q1 2020, an estimated $35K.
Creative Planning first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 27 quarters.
Creative Planning's PDL BioPharma, Inc. position peaked at $222K in Q3 2016.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Creative Planning's 13F filing for Q1 2020, filed 5 May 2020.